Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Climb Bio (CLYM)
NASDAQ:CLYM
Holding CLYM?
Track your performance easily
CLYM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.73 - $11.55
Previous CloseN/A
Volume51.97K
Average Volume (3M)496.36K
Market Cap
$135.27M
Enterprise Value$147.81M
Total Cash (Recent Filing)$21.22M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.18
Next Earnings
May 19, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding67,300,000
10 Day Avg. Volume716,718
30 Day Avg. Volume496,364
Standard Deviation0.32
R-Squared0.00154
Alpha-0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)2047.27
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue2.24K
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.06
Forecast
1Y Price Target
$10.00Price Target Upside412.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Climb Bio News
PremiumCompany Announcements
Climb Bio Inc. Shifts Focus to Immune-Mediated Diseases
PremiumCompany Announcements
Climb Bio to Host Virtual Investor EventRisk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CLYM FAQ
What was Climb Bio’s price range in the past 12 months?
Climb Bio lowest stock price was $1.73 and its highest was $11.55 in the past 12 months.
What is Climb Bio’s market cap?
Climb Bio’s market cap is $135.27M.
When is Climb Bio’s upcoming earnings report date?
Climb Bio’s upcoming earnings report date is May 19, 2025 which is in 121 days.
How were Climb Bio’s earnings last quarter?
Climb Bio released its earnings results on Nov 12, 2024. The company reported -$0.13 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.13.
Is Climb Bio overvalued?
According to Wall Street analysts Climb Bio’s price is currently Undervalued.
Does Climb Bio pay dividends?
Climb Bio does not currently pay dividends.
What is Climb Bio’s EPS estimate?
Climb Bio’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Climb Bio have?
Climb Bio has 67,300,000 shares outstanding.
What happened to Climb Bio’s price movement after its last earnings report?
Climb Bio reported an EPS of -$0.13 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -7.105%.
Which hedge fund is a major shareholder of Climb Bio?
Among the largest hedge funds holding Climb Bio’s share is RA Capital Management. It holds Climb Bio’s shares valued at 160M.
---
Climb Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (412.82% Upside)
$10.00 (412.82% Upside)
Blogger Sentiment
Bullish
CLYM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 105.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.67%
12-Months-Change
Fundamentals
Return on Equity
-42.08%
Trailing 12-Months
Asset Growth
97.10%
Trailing 12-Months
Company Description
Climb Bio
Eliem Therapeutics Inc is a clinical-stage biotechnology company. It is focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems.
---
CLYM Stock 12 Month Forecast
Average Price Target
$10.00
▲(412.82% Upside)
Technical Analysis
ATAI Life Sciences
―
Verrica Pharmaceuticals
―
Bioxcel Therapeutics
―
SELLAS Life Sciences Group
―
Leap Therapeutics
―
Foghorn Therapeutics
―
Best Analysts Covering CLYM
1 Year
1 Year Success Rate
1/2 ratings generated profit
1 Year Average Return
-19.25%
reiterated a buy rating 10 days ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of -19.25% per trade.
---